RESEARCH MONOGRAPH · KDC-MN-255

Gaboxadol (THIP)

May 9, 2026 Kodiac biolabs Research Revised May 19, 2026 3 min read

Our opinion on this compound

65/100

The extrasynaptic GABA-A delta agonist that failed in insomnia and got more interesting for it

Gaboxadol is one of those compounds where the failure story matters more than what it was developed for. Originally synthesized at Lundbeck in the 70s as a structural analog of muscimol, it's a selective agonist at extrasynaptic GABA-A receptors containing the delta subunit (mostly alpha4-beta-delta and alpha6-beta-delta combinations). That selectivity is genuinely unusual and is the whole reason the compound matters scientifically.

Lundbeck and Merck took it into late-stage trials for insomnia in the 2000s and it failed, both on efficacy versus eszopiclone and on a worse-than-expected psychiatric adverse event signal at the doses they tested. Program shut down in 2007. The interesting part is what came after: Ovid Therapeutics revived it as OV101 for Angelman syndrome and Fragile X, on the hypothesis that tonic inhibition mediated by extrasynaptic delta-containing receptors is reduced in those conditions. The Angelman phase 3 readout was mixed but pointed in the right direction for behavioral measures.

What we like is the receptor selectivity. Most GABA-A pharmacology lives on the synaptic alpha1/alpha2/alpha3/alpha5-containing receptors that benzos and z-drugs target. Gaboxadol is one of the only widely available ligands that selectively probes the tonic inhibitory current from the extrasynaptic pool. For circuit-level neuroscience work that distinction is large, and it's been instrumental in studies trying to understand how absence epilepsy, fear extinction, and certain forms of slow-wave sleep depend on tonic versus phasic GABA-A signaling.

The dirty secret of the insomnia failure is that gaboxadol does change sleep architecture in ways thiopental-class hypnotics dont, particularly increasing slow-wave sleep. Whether that translated to subjective sleep improvement is where it fell apart commercially.

Sourcing is doable but vendor variability is real. The hydrochloride is the standard form, NMR and HPLC verification are necessary, and the racemic synthesis used to be the dominant route which complicates SAR comparisons. Look for material where the analytical certificate actually shows the chiral resolution.

Mechanism is well-mapped, evidence is partial, and the compound mostly survives now as a research tool and a niche developmental candidate. We think the underlying biology is more interesting than the clinical history suggests.

Evidence: 60
Mechanism: 85
Reliability: 65
Safety: 65
Sourcing: 60
Value: 65
Signal: 60
Staying power: 60

Plain-language summary Intrigue 70 / 100

Gaboxadol (THIP) is a selective superagonist at extrasynaptic GABA-A receptors that contain the delta subunit, a niche population of receptors that mediate slow tonic inhibition rather than the fast phasic inhibition of standard synaptic GABA-A receptors. Lundbeck and Merck pursued it through the 1990s and 2000s as a hypnotic on the theory that activating these receptors would deliver deeper, more restorative sleep without the cognitive and dependence problems of benzodiazepines. The Phase 3 trials in 2007 ended badly: efficacy was modest and a small but worrisome number of subjects had hallucinations and disorientation. Development for insomnia was halted. The mechanism remains genuinely interesting and the compound is now in revived development for fragile X syndrome and Angelman syndrome under the name OV101. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective extrasynaptic GABA-A delta-subunit agonist

A 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol agonist selective for extrasynaptic GABA-A receptors containing the delta subunit; investigated as a hypnotic.

Abstract

Gaboxadol (THIP; 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol; CAS 64603-91-4; molecular formula C6H8N2O2; molecular weight 140.14) is a selective extrasynaptic GABA-A receptor agonist developed at Lundbeck and Merck through the 1990s and 2000s. Distinct from benzodiazepines and barbiturates by selective binding to GABA-A receptor isoforms containing the delta subunit (alpha4-beta3-delta and alpha6-beta3-delta), which are predominantly extrasynaptic and mediate tonic (continuous, low-amplitude) inhibition rather than the phasic (high-amplitude, transient) inhibition mediated by synaptic alpha1/2/3-beta-gamma2 receptors. The compound is a superagonist at delta-containing receptors (efficacy greater than that of GABA itself). Phase 3 trials in primary insomnia (2007) were halted following adverse psychiatric events including disorientation and hallucinations; development was abandoned. The compound retains research utility as the canonical extrasynaptic delta-GABA-A agonist for academic GABA pharmacology and sleep architecture studies. Plasma half-life is approximately 1.5 to 2 hours.

Mechanism of action

Selective superagonist at extrasynaptic GABA-A receptors containing the delta subunit. Distinct from benzodiazepine pharmacology by extrasynaptic localization.

Reported research dose ranges

Investigational; trial doses 5 to 20 mg per oral administration as a hypnotic. Rodent research 3 to 30 mg/kg.

References

Krogsgaard-Larsen P, et al. GABAA agonists and partial agonists: THIP (gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem Pharmacol 2004.
Wafford KA, Ebert B. Gaboxadol - a new awakening in sleep. Curr Opin Pharmacol 2006.
Mathias S, et al. The GABA uptake inhibitor tiagabine versus gaboxadol on slow wave sleep. Sleep 2005.

Read the full monograph

The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-255 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Gaboxadol (THIP)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs